Okadaic acid promotes angiogenesis via activation of hypoxia-inducible factor-1

Cancer Letters

Volumn 276, Issue 1, 2009, Pages 102-108

  Kim, Young Sun ^a   Ahn, Kook Hee ^a   Kim, Seon Ye ^a   Jeong, Joo Won ^a  

^a Biomedical Science Institute   (South Korea)

Author keywords

Akt; Angiogenesis; HIF 1 ; Okadaic acid

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; OKADAIC ACID; PROTEIN KINASE B; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BIOLOGICAL ACTIVITY; CELL INVASION; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSLATION REGULATION; UMBILICAL VEIN; UPREGULATION;

ANGIOGENESIS INDUCING AGENTS; BLOTTING, WESTERN; CARCINOGENS; CELL MOVEMENT; ENDOTHELIAL CELLS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; NEOVASCULARIZATION, PHYSIOLOGIC; OKADAIC ACID; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60249099640     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.10.034     Document Type: Article

References (45)

1. Fidler I.J., and Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79 (1994) 185-188
2. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
3. Zetter B.R. Angiogenesis and tumor metastasis. Annual review of medicine 49 (1998) 407-424
4. Buchler P., Reber H.A., Buchler M., Shrinkante S., Buchler M.W., Friess H., Semenza G.L., and Hines O.J. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 26 (2003) 56-64
5. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., and Keshert E. Role of HIF-1alpha in hypoxia-mediated apoptosis cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
6. Feldser D., Agani F., Iyer N.V., Pak B., Ferreira G., and Semenza G.L. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Research 59 (1999) 3915-3918
7. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., and Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology 16 (1996) 4604-4613
8. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Molecular and Cellular Biology 21 (2001) 3995-4004
9. 2 sensing. Science (New York, NY) 292 (2001) 464-468
10. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes & Development 12 (1998) 149-162
11. Min J.H., Yang H., Ivan M., Gertler F., Kaelin Jr. W.G., and Pavletich N.P. Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science (New York, NY) 296 (2002) 1886-1889
12. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochemical Pharmacology 64 (2002) 993-998
13. Turner K.J., Moore J.W., Jones A., Taylor C.F., Cuthbert-Heavens D., Han C., Leek R.D., Gatter K.C., Maxwell P.H., Ratcliffe P.J., Cranston D., and Harris A.L. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Research 62 (2002) 2957-2961
14. Arsham A.M., Plas D.R., Thompson C.B., and Simon M.C. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. Journal of Biological Chemistry 277 (2002) 15162-15170
15. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., and Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. Journal of Biological Chemistry 277 (2002) 38205-38211
16. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., and Abraham R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Molecular and Cellular Biology 22 (2002) 7004-7014
17. Jiang B.H., and Liu L.Z. AKT signaling in regulating angiogenesis. Current Cancer Drug Targets 8 (2008) 19-26
18. Jiang B.H., Zheng J.Z., Aoki M., and Vogt P.K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 97 (2000) 1749-1753
19. Li W., Petrimpol M., Molle K.D., Hall M.N., Battegay E.J., and Humar R. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circulation Research 100 (2007) 79-87
20. Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G.L., and Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. Journal of Biological Chemistry 277 (2002) 27975-27981
21. Katschinski D.M., Le L., Schindler S.G., Thomas T., Voss A.K., and Wenger R.H. Interaction of the PAS B domain with HSP90 accelerates hypoxia-inducible factor-1alpha stabilization. Cellular Physiology and Biochemistry 14 (2004) 351-360
22. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends in Molecular Medicine 8 (2002) S55-S61
23. Neckers L. Heat shock protein 90 is a rational molecular target in breast cancer. Breast Disease 15 (2002) 53-60
24. Ryan H.E., Lo J., and Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO Journal 17 (1998) 3005-3015
25. Komori A., Suganuma M., Okabe S., Zou X., Tius M.A., and Fujiki H. Canventol inhibits tumor promotion in CD-1 mouse skin through inhibition of tumor necrosis factor alpha release and of protein isoprenylation. Cancer Research 53 (1993) 3462-3464
26. Suganuma M., Okabe S., Sueoka E., Nishiwaki R., Komori A., Uda N., Isono K., and Fujiki H. Tautomycin: an inhibitor of protein phosphatases 1 and 2A but not a tumor promoter on mouse skin and in rat glandular stomach. Journal of Cancer Research and Clinical Oncology 121 (1995) 621-627
27. Thevenin C., Kim S.J., and Kehrl J.H. Inhibition of protein phosphatases by okadaic acid induces AP1 in human T cells. Journal of Biological Chemistry 266 (1991) 9363-9366
28. Fujiki H., Suganuma M., Okabe S., Sueoka E., Suga K., Imai K., and Nakachi K. A new concept of tumor promotion by tumor necrosis factor-alpha, and cancer preventive agents (-)-epigallocatechin gallate and green tea -- a review. Cancer Detection and Prevention 24 (2000) 91-99
29. Sakai A., Kikuchi Y., Muroi M., Masui T., Furihata C., Uchida E., Takatori K., and Tanamoto K. Overexpression of NP95 mRNA by tumor promoters in the promotion phase of a two-stage BALB/3T3 cell transformation assay. Biological & Pharmaceutical Bulletin 26 (2003) 347-351
30. Wakiya K., and Shibuya M. Okadaic acid stimulates the expression of vascular endothelial growth factor gene. Biochemical and Biophysical Research Communications 265 (1999) 584-588
31. Oikawa T., Suganuma M., Ashino-Fuse H., and Shimamura M. Okadaic acid is a potent angiogenesis inducer. Japanese Journal of Cancer Research 83 (1992) 6-9
32. Reed S.E., Staley E.M., Mayginnes J.P., Pintel D.J., and Tullis G.E. Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors. Journal of Virological Methods 138 (2006) 85-98
33. Saiki I., Fujii H., Yoneda J., Abe F., Nakajima M., Tsuruo T., and Azuma I. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. International Journal of Cancer 54 (1993) 137-143
34. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., and Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Research 60 (2000) 1541-1545
35. Richard D.E., Berra E., and Pouyssegur J. Angiogenesis: how a tumor adapts to hypoxia. Biochemical and Biophysical Research Communications 266 (1999) 718-722
36. Semenza G.L. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Reviews 19 (2000) 59-65
37. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO Journal 22 (2003) 4082-4090
38. Hon W.C., Wilson M.I., Harlos K., Claridge T.D., Schofield C.J., Pugh C.W., Maxwell P.H., Ratcliffe P.J., Stuart D.I., and Jones E.Y. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 417 (2002) 975-978
39. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., and Kim K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111 (2002) 709-720
40. Masson N., Willam C., Maxwell P.H., Pugh C.W., and Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO Journal 20 (2001) 5197-5206
41. Minet E., Mottet D., Michel G., Roland I., Raes M., Remacle J., and Michiels C. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Letters 460 (1999) 251-256
42. Lando D., Gorman J.J., Whitelaw M.L., and Peet D.J. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. European Journal of Biochemistry/FEBS 270 (2003) 781-790
43. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., Pavletich N., Chau V., and Kaelin W.G. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nature Cell Biology 2 (2000) 423-427
44. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature Cell Biology 4 (2002) 648-657
45. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., and Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Molecular Cell 10 (2002) 151-162